Company intelligence / Profile preview

Stealth BioTherapeutics

George Town, Cayman Islands
Ownership
Public · MITO
Employees
~38
Development stage
NDA
01

Overview

Stealth BioTherapeutics develops therapies targeting mitochondrial dysfunction. Its lead candidate elamipretide has completed pivotal studies for Barth syndrome and primary mitochondrial myopathy, with an NDA under FDA review for Barth syndrome as of May 2025. The company also reported a highly protective effect on photoreceptor loss in dry AMD Phase 2 trials. Next-generation candidates like bevemipretide/SBT‐272 are advancing through early clinical stages for rare neurological and ophthalmic diseases.[6]

Therapeutic areas
OphthalmologyNeurologyRare DiseasesCardiovascular
Modalities
Peptide therapeutics[3][5]Small molecules (pipeline includes SBT series)[3][5]
Industry
Biotech
02

Drug pipeline

8 assets

elamipretide

Approved

7 more assets in the full pipeline.

Request access →
03

Financials

Market cap
$0
Total revenue
$0
Enterprise value
$-20.1M

Beyond the preview

Go deeper on Stealth BioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stealth BioTherapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call